SPTX — Seaport Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2042347 ·
Last close
$17.91
Market Cap
$958.73M
52W High
$28.38
52W Low
$14.85
ADV30
263,443
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,543,000 | -25,408,000 | 227,673,000 | 52,909,000 | 343,294,000 |
| Mar 2025 | 0 | — | -16,185,000 | -13,125,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-40,377,000
Investing CF
$-197,701,000
Financing CF
$-783,000
CapEx
$-54,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-139,517,000
Inventory
—
Receivables
$3,277,000
ST Investments
$129,696,000
EBIT TTM
$-43,728,000
Pretax Income TTM
$-37,983,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -87,294,000 | -74,881,000 | 249,009,000 | 341,554,000 | -92,545,000 | -77,942,000 |
| Dec 2024 | 0 | -52,416,000 | -46,879,000 | 315,777,000 | 340,626,000 | -24,849,000 | -29,629,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$227,673,000
Forward EPS
$-2.57
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AKTS | Aktis Oncology, Inc. | $953.47M | $17.74 | — |
| ANRO | Alto Neuroscience, Inc. | $942.99M | $24.03 | — |
| LTGO | Latigo Biotherapeutics, Inc. | $980.57M | $14.79 | — |
| KURA | Kura Oncology, Inc. | $935.87M | $10.52 | — |
| SVRA | Savara Inc | $992.37M | $4.83 | — |
News headlines (Yahoo Finance, 1h cache)
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
2026-10-07 17:00 · Yahoo
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
2026-10-07 11:00 · Yahoo
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
2026-09-22 19:00 · Yahoo
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
2026-09-09 11:00 · Yahoo
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
2026-08-31 11:00 · Yahoo
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
2026-08-20 14:40 · Yahoo
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-08-03 11:00 · Yahoo
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-06-08 11:05 · Yahoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
2026-06-08 11:00 · Yahoo
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
2026-06-01 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.